Beta Bionics (BBNX) EBITDA Margin (2024 - 2026)

Beta Bionics has disclosed EBITDA Margin across 3 years of filings, most recently posting 81.06% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 81.06%, up 8040.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 60.57% (up 4071.0% YoY), and the FY2025 annual result was 72.68%, up 1151.0% from the prior year.
• EBITDA Margin came in at 81.06% for Q1 2026 at Beta Bionics, down from 41.77% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 41.77% in Q4 2025 to a low of 161.47% in Q1 2025.
• The 3-year median for EBITDA Margin is 81.06% (2026), against an average of 83.18%.
• Across the five-year window, EBITDA Margin sank 6419 bps in 2025 and soared 8040 bps in 2026, its largest moves.
• Beta Bionics' EBITDA Margin stood at 88.56% in 2024, then jumped by 53 bps to 41.77% in 2025, then tumbled by 94 bps to 81.06% in 2026.
• The last three EBITDA Margin figures came in at 81.06% (Q1 2026), 41.77% (Q4 2025), and 51.39% (Q3 2025), per Business Quant data.